FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy-Reference-Cited by-同舟云学术

FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy

Published:2023-12 Issue:12 Volume:4 Page:101306
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Mina Erica,Wyart Elisabeth,Sartori Roberta,Angelino Elia,Zaggia Ivan,Rausch Valentina,Maldotti Mara,Pagani Alessia,Hsu Myriam Y.,Friziero Alberto,Sperti Cosimo,Menga Alessio,Graziani Andrea,Hirsch Emilio,Oliviero Salvatore,Sandri Marco,Conti Laura,Kautz Léon,Silvestri Laura,Porporato Paolo E.^ORCID

Funder

Horizon 2020 Framework Programme

Ministero dell'Istruzione dell'Universita e della Ricerca

European Research Council

Consorzio Interuniversitario Biotecnologie

Associazione Italiana per la Ricerca sul Cancro

Horizon 2020

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference84 articles.

1. Definition and classification of cancer cachexia: an international consensus;Fearon;Lancet Oncol.,2011

2. Cachexia as a major underestimated and unmet medical need: facts and numbers;von Haehling;J Cachexia Sarcopenia Muscle,2010

3. Cancer cachexia and fat-muscle physiology;Fearon;N. Engl. J. Med.,2011

4. Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia;Rausch;Oncogenesis,2021

5. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival;Zhou;Cell,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicomponent comprehensive confirms that erythroferrone is a molecular biomarker of pan-cancer;Heliyon;2024-03